- Conditions
- Focal Segmental Glomerulosclerosis
- Interventions
- Plasma exchange, Cyclophosphamide
- Procedure · Drug
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Eligibility
- Not listed
- Enrollment
- 15 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2000 – 2014
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Focal Segmental Glomerulosclerosis
- Interventions
- LIPOSORBER® LA-15 System
- Device
- Lead sponsor
- Kaneka Medical America LLC
- Industry
- Eligibility
- Up to 21 Years
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2029
- U.S. locations
- 12
- States / cities
- Loma Linda, California • Los Angeles, California • Wilmington, Delaware + 9 more
- Conditions
- Focal Segmental Glomerulosclerosis (FSGS)
- Interventions
- IXP
- Drug
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024
- U.S. locations
- 3
- States / cities
- Miami, Florida • St. Petersburg, Florida • San Antonio, Texas
- Conditions
- Focal Segmental Glomerulosclerosis
- Interventions
- sparsentan, Irbesartan
- Drug
- Lead sponsor
- Travere Therapeutics, Inc.
- Industry
- Eligibility
- 8 Years to 75 Years
- Enrollment
- 371 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 87
- States / cities
- Mesa, Arizona • Phoenix, Arizona • Los Angeles, California + 73 more
- Conditions
- Focal Segmental Glomerulosclerosis, Nephrotic Syndrome, Steroid Resistant Nephrotic Syndrome, Chronic Kidney Disease
- Interventions
- Cardiovascular Assessment, Renal Assessment, Genetic Evaluation
- Other
- Lead sponsor
- Northwell Health
- Other
- Eligibility
- 6 Months to 21 Years
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 1
- States / cities
- New Hyde Park, New York
- Conditions
- Focal Segmental Glomerulosclerosis
- Interventions
- No intervention
- Other
- Lead sponsor
- Children's Hospital Medical Center, Cincinnati
- Other
- Eligibility
- Up to 21 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 2
- States / cities
- Cincinnati, Ohio • Pittsburgh, Pennsylvania
- Conditions
- Glomerular Disease
- Interventions
- Cholecalciferol, 2000 or 4000 IUs by mouth daily for 12 weeks
- Dietary Supplement
- Lead sponsor
- Children's Hospital of Philadelphia
- Other
- Eligibility
- 5 Years to 30 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 5
- States / cities
- Wilmington, Delaware • Baltimore, Maryland • New Hyde Park, New York + 1 more
- Conditions
- Focal Segmental Glomerulosclerosis
- Interventions
- BI 764198, Placebo
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 286 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 73
- States / cities
- Alabaster, Alabama • Huntsville, Alabama • Surprise, Arizona + 62 more
- Conditions
- FSGS, Focal Segmental Glomerulosclerosis, Glomerulosclerosis
- Interventions
- Placebo, CCX140-B
- Other · Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 9
- States / cities
- Phoenix, Arizona • Torrance, California • Shreveport, Louisiana + 6 more
- Conditions
- Proteinuria, Immunoglobulin A (IgA) Nephropathy, Focal Segmental Glomerulosclerosis, Kidney Transplant
- Interventions
- Sparsentan
- Drug
- Lead sponsor
- Travere Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 8
- States / cities
- Birmingham, Alabama • New York, New York • Morrisville, North Carolina + 5 more
- Conditions
- Nephrosis, Focal Lipoid Glomerulosclerosis
- Interventions
- Oral dexamethasone
- Drug
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Eligibility
- 2 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2010
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- FSGS, Proteinuria
- Interventions
- Rituximab
- Drug
- Lead sponsor
- George W. Burke
- Other
- Eligibility
- 7 Years to 65 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Glomerulosclerosis, Focal Segmental, Minimal Change Disease, Diabetic Nephropathies
- Interventions
- FSGS/TR-MCD, Diabetic Nephropathy (DN)
- Other
- Lead sponsor
- Goldfinch Bio, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 18
- States / cities
- Mesa, Arizona • Glendale, California • Victorville, California + 12 more
- Conditions
- Focal Glomerulosclerosis
- Interventions
- Rosiglitazone (Avandia), Adalimumab (Humira)
- Drug
- Lead sponsor
- Northwell Health
- Other
- Eligibility
- 2 Years to 40 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2007
- U.S. locations
- 2
- States / cities
- New Hyde Park, New York • Chapel Hill, North Carolina
- Conditions
- Idiopathic Focal Segmental Glomerulosclerosis
- Interventions
- Acthar Gel
- Drug
- Lead sponsor
- Mallinckrodt ARD LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 63 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 21
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Chula Vista, California + 16 more
- Conditions
- Nephrotic Syndrome
- Interventions
- ADX-629
- Drug
- Lead sponsor
- Aldeyra Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023
- U.S. locations
- 11
- States / cities
- Northridge, California • Aurora, Colorado • Lauderdale Lakes, Florida + 8 more
- Conditions
- Focal Segmental Glomerulosclerosis, Nephrotic Syndrome, End Stage Renal Disease, Kidney Failure, Unexplained Proteinuria
- Interventions
- Not listed
- Lead sponsor
- Beth Israel Deaconess Medical Center
- Other
- Eligibility
- Not listed
- Enrollment
- 2,050 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 1996 – 2035
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Fibrosis, Focal Glomerulosclerosis, Kidney Failure, Nephrotic Syndrome, Proteinuria
- Interventions
- Pirfenidone
- Drug
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2008
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Glomerulosclerosis, Focal Segmental
- Interventions
- Losmapimod
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 8
- States / cities
- Los Angeles, California • Stanford, California • New Orleans, Louisiana + 5 more
- Conditions
- Focal Segmental Glomerulosclerosis (FSGS)
- Interventions
- VX-147
- Drug
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- FSGS, Renal Transplantation, Kidney Transplantation
- Interventions
- Acthar
- Drug
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Focal Glomerulosclerosis
- Interventions
- Sirolimus
- Drug
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Eligibility
- Not listed
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2005
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Nephrotic Syndrome in Children, Minimal Change Disease, Focal Segmental Glomerulosclerosis
- Interventions
- Transcutaneous auricular vagus nerve stimulation, Sham device
- Device
- Lead sponsor
- Northwell Health
- Other
- Eligibility
- 3 Years to 17 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 2
- States / cities
- New Hyde Park, New York • Philadelphia, Pennsylvania
- Conditions
- Proteinuria
- Interventions
- Not listed
- Lead sponsor
- University of Miami
- Other
- Eligibility
- Up to 25 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2026
- U.S. locations
- 1
- States / cities
- Miami, Florida